ORSENIX

Orsenix is a clinical-stage biotech company developing a novel oral form of arsenic trioxide (ATO) to treat acute promyelocytic leukemia (APL) and other cancers. It is committed to transforming cancer treatment with innovative oral therapies that give patients the freedom to live their everyday lives.